ALCLS.PA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 05:49):

Stats
Today's Volume	15 217.00
Average Volume	85 076.00
Market Cap	171.84M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $0 ) 2024-06-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.810
ATR14	$0.0190 (0.79%)

Volume Correlation

Long: 0.10 (neutral)

Short: -0.88 (strong negative)

Signal:(53.319) Neutral

Cellectis SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cellectis SA Correlation - Currency/Commodity

0.29
( neutral )

0.40
( neutral )

0.00
( neutral )

-0.62
( weak negative )

-0.31
( neutral )

Cellectis SA Financials

Annual	2022
Revenue:	$19.17M
Gross Profit:	$17.40M (90.76 %)
EPS:	$-2.17

FY	2022
Revenue:	$19.17M
Gross Profit:	$17.40M (90.76 %)
EPS:	$-2.17

FY	2021
Revenue:	$57.29M
Gross Profit:	$25.93M (45.26 %)
EPS:	$-1.910

FY	2020
Revenue:	$73.95M
Gross Profit:	$37.67M (50.95 %)
EPS:	$-1.910

Financial Reports:

No articles found.

Cellectis SA

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.